Comparing the lasting effects: post COVID vs. non-COVID acute respiratory infections

Symptom profiles between individuals with prior COVID-19 and those with other acute respiratory infections (ARIs).

Breakthrough research unveils β-cell dynamics in Type 1 diabetes

About eight million people live with Type 1 diabetes (T1D) worldwide, a chronic autoimmune condition in which the body attacks and destroys its own insulin-producing

February 26, 2024

Enzymatic RNA synthesis paves the way for sustainable therapeutics

While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne

July 12, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer – Biotech Investments

Issuer: CureVac / Key word(s): Personnel 04.11.2024 / 13:03 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Strengthens Leadership Team

November 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.